Edmond de Rothschild Investment Partners (EdRIP), Vesalius Biocapital Partners, Mitsubishi Pharma Corporate Venture and other investors have provided Swiss biopharma GenKyoTex with CHF 25m of early-stage funding.
Exit of UK-based software provider set to generate 40%-plus IRR; Baird advised on auction
New partner Sascha Konwalski joins Frankfurt office; US law firm to open new offices in Europe
French drug maker is the first divestment from liquidated fund Novalpina I, now managed by Berkeley Research Group
Ylva Hannestad joins GP’s client engagement around sustainability agenda